President Trump plans to gradually raise tariffs on imported pharmaceuticals to 250% over 18 months to push U.S.-based drug production. Major firms like AstraZeneca and Eli Lilly have already pledged U.S. investments. Industry groups warn of cost spikes. Tariffs on chips also loom. XLV sentiment is 'bullish' on Stocktwits.